Sarıcı, A. Et Al. 2023. The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. İstanbul Medical Journal , vol.24, no.2 , 216-220.

Sarıcı, A., Erkurt, M. A., Kuku, İ., Kaya, E., Berber, İ., Biçim, S., ... Hidayet, E.(2023). The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. İstanbul Medical Journal , vol.24, no.2, 216-220.

Sarıcı, AHMET Et Al. "The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience," İstanbul Medical Journal , vol.24, no.2, 216-220, 2023

Sarıcı, AHMET Et Al. "The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience." İstanbul Medical Journal , vol.24, no.2, pp.216-220, 2023

Sarıcı, A. Et Al. (2023) . "The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience." İstanbul Medical Journal , vol.24, no.2, pp.216-220.

@article{article, author={AHMET SARICI Et Al. }, title={The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience}, journal={İstanbul Medical Journal}, year=2023, pages={216-220} }